Trials / Recruiting
RecruitingNCT06060405
Durvalumab and Oleclumab in Resectable PDAC
Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells. |
| DRUG | Oleclumab | Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73. |
Timeline
- Start date
- 2023-11-29
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
- First posted
- 2023-09-29
- Last updated
- 2024-01-08
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06060405. Inclusion in this directory is not an endorsement.